CEO Paul Hudson talks about latest Sanofi headlines at the Financial Times' Global Pharma and Biotech Summit on Nov. 8. (Credit: Reynald Castañeda for Endpoints News)
November 9, 2023 03:39 AM ESTUpdated 06:01 AM
People
Pharma

Sanofi CEO re­it­er­ates R&D bet is best long-term ap­proach, ad­dress­es probe on mar­ket ma­nip­u­la­tion al­le­ga­tions

Reynald Castañeda

Deputy Editor

Al­though Sanofi CEO Paul Hud­son was at the Fi­nan­cial Times’ Glob­al Phar­ma and Biotech Sum­mit to talk about AI, there was no avoid­ing the ques­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

Roche out­lines com­mer­cial man­u­fac­tur­ing strat­e­gy for GLP-1/GIP as­sets 

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times